Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pradofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.73 |
| ▸ | HPGD | P15428 | 5/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | TOP2A | P11388 | 5/20 | 0.44 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pradofloxacin SCHEMBL7488977 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL2201509 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7678035 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL30595280 | 0.99 | ALDH1A1 (0.74) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7962325 | 0.99 | ALDH1A1 (0.74) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7962442 | 0.96 | ALDH1A1 (0.68) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7976296 | 0.95 | KDM4E (0.69) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL9181426 | 0.92 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL7962516 | 0.90 | KDM4E (0.67) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Pradofloxacin SCHEMBL7975579 | 0.90 | KDM4E (0.63) | ALDH1A1KDM4EHPGDHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| EP-4507694-A1 | SOFT CHEWABLE VETERINARY DOSAGE FORM | KRKA, d.d., Novo mesto (SI) | 2025-02-19 | — | — | EP | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| US-20240182504-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BIOVINC LLC (US) | 2024-06-06 | — | — | US | claimed |
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2023-12-12 | — | — | US | claimed |
| WO-2023198476-A1 | SOFT CHEWABLE VETERINARY DOSAGE FORM | KRKA, D.D., NOVO MESTO (SI) | 2023-10-19 | — | — | WO | claimed |
| US-20230285572-A1 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC | 2023-09-14 | — | — | US | claimed |
| WO-2023137387-A2 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2023137373-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| US-20040247560-A1 | Pharmaceutical preparations comprising iox exchange resins charged with active ingrdients | BAYER HEALTHCARE AG (DE) | 2004-12-09 | — | — | US | claimed |
| WO-2004082658-A1 | CONTROLLED RELEASE SYSTEM CONTAINING SACCHAROSE ACETATE ISOBUTYRATE | BAYER HEALTHCARE AG (DE) | 2004-09-30 | — | — | WO | claimed |
| EP-1133496-B1 | CRYSTAL MODIFICATION A OF 8-CYANO-1- CYCLOPROPYL -7-(1S,6S-2, 8-DIAZABICYCLO 4.3.0]NONAN -8-YL)-6- FLUORO-1, 4-DIHYDRO- 4-OXO-3- QUINOLINE CARBOXYLIC ACID | BAYER HEALTHCARE AG (DE) | 2004-04-21 | — | — | EP | claimed |
| US-6664268-B1 | Easy to handle; reduced water vapor absorption | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-16 | — | — | US | claimed |
| WO-2003101422-A2 | PHARMACEUTICAL PREPARATIONS FOR ORAL ADMINISTRATION, CONTAINING ION-EXCHANGE RESINS LOADED WITH ACTIVE INGREDIENTS AND INTRINSICALLY VISCOUS GELLING AGENTS AS THICKENING AGENTS | BAYER HEALTHCARE AG (DE) | 2003-12-11 | — | — | WO | claimed |
| US-6649762-B1 | Exposing amorphous crystals to humidity, then drying and heating above rearrangement temperature; quinolone antibiotics | BAYER AKTIENGESELLSCHAFT (DE) | 2003-11-18 | — | — | US | claimed |
| US-6492391-B1 | TREATING BACTERIAL INFECTION | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-10 | — | — | US | claimed |
| EP-1155018-B1 | CRYSTAL MODIFICATION C OF 8-CYANO-1-CYCLOPROPYL-7- (1S, 6S-2,8- DIAZABICYCLO - 4.3.0] NONAN-8-YL) -6-FLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLINE CARBOXYLIC | BAYER AG (DE) | 2002-10-30 | — | — | EP | claimed |
| EP-1133495-B1 | SEMI-HYDROCHLORIDE OF 8-CYAN-1- CYCLOPROPYL -7-(1S,6S-2 ,8-DIAZABICYCLO 4.3.0]NONAN -8-YL)-6- FLUORO-1, 4-DIHYDRO -4-OXO-3- QUINOLINE CARBOXYLIC ACID | BAYER AG (DE) | 2002-10-09 | — | — | EP | claimed |
| US-6436955-B1 | STORAGE STABLE, LESS HYGROSCOPIC, BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040247560-A1 | Pharmaceutical preparations comprising iox exchange resins charged with active ingrdients | SLCO4C1, SLCO2A1, SLCO1B1 | ALDH1A1 2193/4885KDM4E 4077/4885HPGD 1600/4885 |
| US-20240182504-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BPGM, PHPT1, NQO2 | ALDH1A1 2346/4885KDM4E 3437/4885HPGD 266/4885 |
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BPGM, PHPT1, NQO2 | ALDH1A1 2346/4885KDM4E 3437/4885HPGD 266/4885 |
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | PTMS, CYP24A1, PHPT1 | ALDH1A1 4057/4885KDM4E 476/4885HPGD 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.